Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof

1. A compound of formula (I)

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug thereof, wherein R 1 , R 2 and R 3 are independently selected from the group consisting of hydrogen, halogen, alkyl and haloalkyl;

L is a bond or C 1-6 alkyl;

A is a ring selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycle, aryl and heteroaryl; wherein each A is independently substituted with 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, halogen, cyano, hydroxyl, alkoxy, haloalkoxy, —SH, —S(alkyl), —S(O)alkyl, —S(O) 2 alkyl, —S(O) 2 NH 2 , —S(O) 2 N(H)alkyl, —S(O) 2 N(alkyl) 2 , —NH 2 , —N(H)alkyl, —N(alkyl) 2 , —C(O)OH, —C(O)O(alkyl), —C(O)alkyl, —C(O)NH 2 , —C(O)N(H)alkyl, —C(O)N(alkyl) 2 , cyanoalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, -alkylSH, -alkylS(alkyl), -alkylS(O)alkyl, -alkylS(O) 2 alkyl, -alkylS(O) 2 NH 2 , -alkylS(O) 2 N(H)alkyl, -alkylS(O) 2 N(alkyl) 2 , -alkylNH 2 , -alkylN(H)alkyl, -alkylN(alkyl) 2 , -alkylC(O)OH, -alkylC(O)O(alkyl), -alkylC(O)alkyl, -alkylC(O)NH 2 , -alkylC(O)N(H)alkyl, and -alkylC(O)N(alkyl) 2 ;

G is an aryl ring; wherein each G is independently substituted with 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of cyano, —OR a , —OC(O)R a , —OC(O)NR a R b , —SR a , —S(O)R a , —S(O) 2 R a , —S(O) 2 NR a R b , —NR a R b , —C(O)OR a , —C(O)R a , —C(O)NR a R b , R c , haloalkyl, cyanoalkyl, -alkylOR a , -alkylOC(O)R a , -alkylOC(O)NR a R b , -alkylSR a , -alkylS(O)R a , -alkylS(O) 2 R a , -alkylS(O) 2 NR a R b , -alkylNR a R b , -alkylC(O)OR a , -alkylC(O)R a , -alkylC(O)NR a R b , and -alkyl-R c ;

wherein R a , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, heteroaryl, arylalkyl and heteroarylalkyl; wherein the cycloalkyl, cycloalkenyl, heterocycle, aryl, heteroaryl, aryl moiety of the arylalkyl and the heteroaryl moiety of the heteroarylalkyl are independently substituted with 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, halogen, haloalkyl, cyanoalkyl, hydroxyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, —SH, —S(alkyl), —S(O)alkyl, —S(O) 2 alkyl, —S(O) 2 NH 2 , —S(O) 2 N(H)alkyl, —S(O) 2 N(alkyl) 2 , —NH 2 , —N(H)alkyl, —N(alkyl) 2 , —C(O)OH, —C(O)O(alkyl)—C(O)O(aryl), —C(O)alkyl, —C(O)NH 2 , —C(O)N(H)alkyl, and —C(O)N(alkyl) 2 ;

wherein R b , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocycle, heteroaryl, arylalkyl and heteroarylalkyl; wherein each of the cycloalkyl, aryl, heterocycle, heteroaryl, aryl moiety of the arylalkyl and heteroaryl moiety of the heteroarylalkyl is independently substituted with 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, halogen, haloalkyl, cyanoalkyl, hydroxyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, —SH, —S(alkyl), —S(O)alkyl, —S(O) 2 alkyl, —S(O) 2 NH 2 , —S(O) 2 N(H)alkyl, —S(O) 2 N(alkyl) 2 , —NH 2 , —N(H)alkyl, —N(alkyl) 2 , —C(O)OH, —C(O)O(aryl), —C(O)alkyl, —C(O)NH 2 , —C(O)N(H)alkyl, and —C(O)N(alkyl) 2 ; and

wherein R c , at each occurrence, is a ring independently selected from the group consisting cycloalkyl, cycloalkenyl, heterocycle, aryl and heteroaryl; wherein each R c is independently substituted with 0, 1, 2, 3, 4 or 5 substituents selected from the group consisting of alkyl, halogen, cyano, hydroxyl, alkoxy, haloalkoxy, —SH, —S(alkyl), —S(O)alkyl, —S(O) 2 alkyl, —S(O) 2 NH 2 , —S(O) 2 N(H)alkyl, —S(O) 2 N(alkyl) 2 , —NH 2 , —N(H)alkyl, —N(alkyl) 2 , —C(O)OH, —C(O)O(alkyl), —C(O)alkyl, —C(O)NH 2 , —C(O)N(H)alkyl, ——C(O)N(alkyl) 2 ; haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, -alkylSH, -alkylS(alkyl), -alkylS(O)alkyl, -alkylS(O) 2 alkyl, -alkylS(O) 2 NH 2 , -alkylS(O) 2 N(H)alkyl, -alkylS(O) 2 N(alkyl) 2 , -alkylNH 2 , -alkylN(H)alkyl, -alkylN(alkyl) 2 , -alkylC(O)OH, -alkylC(O)O(alkyl), -alkylC(O)alkyl, -alkylC(O)NH 2 , -alkylC(O)N(H)alkyl, and -alkylC(O)N(alkyl) 2 .

2. The compound of claim 1 , wherein A is heteroaryl.

3. The compound of claim 2 , wherein A is pyridyl.

4. The compound of claim 3 , wherein L is a bond.

5. The compound of claim 4 , wherein G is aryl.

6. The compound of claim 5 , wherein G is phenyl.

7. The compound of claim 6 , wherein the compound is selected from the group consisting of

N-(4-tert-butylphenyl)-6-(3-chloropyridin-2-yl)-1,2-benzisothiazol-3-amine 1,1-dioxide;

6-(3-chloropyridin-2-yl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-1,2-benzisothiazol-3-amine 1,1-dioxide;

1-(4-{[6-(3-chloropyridin-2-yl)-1,1-dioxido-1,2-benzisothiazol-3-yl]amino}phenyl)ethanone;

N-[4-(8-azabicyclo[3.2.1]oct-8-yl)phenyl]-6-(3-chloropyridin-2-yl)-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-(4-chloro-3-fluorophenyl)-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-[4-(2,2-dichloro-1-methylcyclopropyl)phenyl]-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

2-[4-({1,1-dioxido-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-yl}amino)phenyl]-2-methylpropanenitrile;

N-(4-chlorophenyl)-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-[4-(trifluoromethyl)phenyl]-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-(4-tert-butylphenyl)-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-(4-azepan-1-ylphenyl)-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-[4-(methylsulfonyl)phenyl]-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-[4-(azepan-1-ylsulfonyl)phenyl]-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

1-[4-({1,1-dioxido-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-yl}amino)phenyl]ethanone;

N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3,5-difluorophenyl]-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

6-[3-(trifluoromethyl)pyridin-2-yl]-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-[4-(8-azabicyclo[3.2.1]oct-8-yl)-3-fluorophenyl]-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide;

N-[4-(trifluoromethoxy)phenyl]-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide; and

N-[4-(8-azabicyclo[3.2.1]oct-8-ylsulfonyl)phenyl]-6-[3-(trifluoromethyl)pyridin-2-yl]-1,2-benzisothiazol-3-amine 1,1-dioxide.

8. The compound of claim 3 wherein L is a C 1-6 alkyl.

9. The compound of claim 8 , wherein G is aryl.

10. The compound of claim 9 , wherein G is phenyl.

11. The compound of claim 10 , wherein the compound is selected from the group consisting of N-(4-tert-butylbenzyl)-6-(3-chloropyridin-2-yl)-1,2-benzisothiazol-3-amine 1,1-dioxide; and N-[2-(4-tert-butylphenyl)ethyl]-6-(3-chloropyridin-2-yl)-1,2-benzisothiazol-3-amine 1,1-dioxide.

12. The compound of claim 2 wherein A is pyrimidinyl.

13. The compound of formula 12, wherein L is a bond.

14. The compound of claim 13 , wherein G is aryl.

15. The compound of claim 14 , wherein G is phenyl.

16. The compound of claim 15 , wherein the compound is selected from the group consisting of N-(4-tert-butylphenyl)-6-pyrimidin-2-yl-1,2-benzisothiazol-3-amine 1,1-dioxide; and 6-pyrimidin-2-yl-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-1,2-benzisothiazol-3-amine 1,1-dioxide.

17. The compound of claim 2 wherein L is C 1-6 alkyl.

18. The compound of claim 17 wherein G is aryl.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof.